Pulmonary Involvement in Patients with Hematological Malignancies

1. Front Matter

   Pages i-xix

   PDF

2. Preamble and Introduction

   1. Front Matter

      Pages 1-1

      PDF

   2. Managing Patients with Hematological Malignancies for 25 Years

      • Benoit Schlemmer

      Pages 3-4

   3. Pulmonary Involvement in Patients with Hematological Malignancies

      • Élie Azoulay

      Pages 5-7

   4. Respiratory Infections in Patients with Hematological Malignancies

      • Ayman O. Soubani

      Pages 9-38

3. Epidemiology

   1. Front Matter

      Pages 39-39

      PDF

   2. Epidemiology of Respiratory Events in Patients with HM (Not Including ICU)

      • Georg Maschmeyer

      Pages 41-45

   3. Epidemiology of Acute Respiratory Failure in Patients with HM (ICU Only)

      • Carlos Agustí, Carmen Lucena, Antoni Torres

      Pages 47-55

   4. Noninfectious Lung Involvement in Patients with Hematological Malignancies (Excluding BMT)

      • Bernard Maitre

      Pages 57-62

   5. Noninfectious Pulmonary Involvement in Hematopoietic Stem Cell or Bone Marrow Transplant Recipients

      • Bekele Afessa

      Pages 63-81

   6. Are There Any Pulmonary Issues Specifically Related to Cord Blood Transplants?

      • Jonathan Gutman

      Pages 83-85

   7. Cardiovascular Complications of Cancer Therapeutics

      • Aarif Y. Khakoo, Callie S. Kwartler

      Pages 87-115

   8. Prophylaxis: Peace of Mind?

      • Benoit Guery, Karine Faure

      Pages 117-119

4. Diagnostic Strategy in HM Patients

   1. Front Matter

      Pages 121-121

      PDF

5. Diagnostic Strategy In HM Patients

   1. How Type of Malignancy and Treatment Assist in the Etiological Diagnosis

      • Alexandre Boyer, Didier Gruson

      Pages 123-129

   2. Contribution of Radiology in Patients with Hematological Malignancies and Pulmonary Involvement

      • Claus Peter Heussel

      Pages 131-146

   3. Is There Still a Place for Transbronchial Lung Biopsy or Other Lung Biopsy Techniques?

      • Christophe Dooms, Vincent Ninane

      Pages 147-153

   4. The Increasing Role for Core Needle Biopsy of Pulmonary Lesions in Immunocompromised Patients

      • Cédric de Bazelaire, Raphael Calmon, Marion Chapelier, Amélie Pluvinage, Eric de Kerviler

      Pages 155-173

   5. Minimally Invasive Diagnostic Strategy in Immunocompromised Patients with Pulmonary Infiltrates

      • Laurent Camous, Virginie Lemiale, Achille Kouatchet, David Schnell, Sandra de Miranda, Élie Azoulay

      Pages 175-189

   6. Pleural Effusions and Thoracentesis in Patients with Hematological Malignancies

      • Michael G. Alexandrakis, Paschalis Steiropoulos, Demosthenes Bouros

      Pages 191-208

The number of patients treated for hematological malignancies is increasing steadily. To maximize cure rates, aggressive treatments have been introduced, including high-dose chemotherapy, stem cell transplantation, and targeted therapies. As a result, overall and disease-free survival rates have improved substantially, but at the price of life-threatening toxic and infectious complications that chiefly target the lung. This book provides clinicians caring for patients with hematological malignancies with detailed, up-to-date information on all relevant aspects of pulmonary involvement. Individual sections are devoted to epidemiology, diagnostic strategy, lung infections, non-infectious pulmonary involvement, and treatment, including decision making in patients with acute respiratory failure. Each of these sections contains a number of chapters, all written by leading international experts. In addition, the reader’s attention is drawn to important "pearls" relating to each condition.

• Bone Marrow Transplantation
• Bronchoscopy and BAL
• Drug Related Pulmonary Toxicity
• Neutropenia
• Pneumocystis
• infectious diseases

From the reviews:

“This is a detailed, multiauthored review of infectious, inflammatory, and thromboembolic complications in patients with a variety of hematological cancers. … Practitioners with an interest in hematological malignancy and intensivists providing critical care resources for management of these patients are an appropriate audience for this work coming from an international panel of authors, the majority of whom are from France. … This unique book effectively reviews the current therapy, incidence, and outcomes for this complex patient group.” (David J. Dries, Doody’s Review Service, December, 2011)

• Service de Réanimation Médicale, Hôpital Saint Louis, Paris, France

  Elie Azoulay

Dr Élie Azoulay is the Assistant Director of the Medical ICU at the Saint-Louis Teaching Hospital, Paris, France. He is a professor of medicine at the Denis Diderot Paris 7 University. From his background as a pulmonologist, Dr Azoulay developed a strong research focus on acute respiratory failure in immunocompromized patients. His PhD work was on respiratory physiology in an experimental model of cancer chemotherapy-related pulmonary toxicity. He has several published clinical research studies on acute respiratory failure in hematology and oncology patients. Also, Dr Azoulay leads a collaborative multicenter group that has performed observational studies, large cohort studies, and randomized controlled trials in cancer patients with ARF. His second major field of interest in clinical research is communication with family members of ICU patients. He constituted a research group in 1997 (the French Famirea Study Group) to evaluate the ability of critical care clinicians to provide effective information to ICU patients and families. Several of his published studies investigated the burden of critical illness in relatives and in ICU clinicians. The group’s major aim is to identify targets for improvement and to test potential interventions in international RCTs in order to advance ICU practices in the field of information and communication. In addition to clinical and research activities, Dr Azoulay teaches pulmonary medicine, critical care medicine, and ethics at the Paris Medical School. He is also associate editor of Intensive Care Medicine, in the editorial board of the American Journal of respiratory and Critical Care medicine, and the chairman of the ethics section of the ESICM. Dr Azoulay is a member of the European board of Pfizer and Gilead.

Policies and ethics